Myths and misperceptions — industry’s stumbling blocks

Our industry is rife with myths that shape its sectors’ perceptions of each other. The cost is that it slows down, impairs, or even prevents the transfer of ideas and assets that’s fundamental to the journey of a therapy from lab to patient.

It takes a delicate constellation of players to pass the ball along in this journey, and as the biopharma ecosystem evolves, its members aren’t always fast to realize the changes happening around them. This means that despite a lot of progress, there’s still wasted energy and lost opportunities because of these myths, misperceptions and misreadings of incentives...